{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:44:01Z","timestamp":1782265441808,"version":"3.54.5"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"am","delay-in-days":305,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cyto.2023.156234","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T17:01:13Z","timestamp":1685638873000},"page":"156234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Etoposide: A rider on the cytokine storm"],"prefix":"10.1016","volume":"168","author":[{"given":"Christian","family":"Bailly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2023.156234_b0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/biom11040603","article-title":"Podophyllotoxin: History, recent advances and future prospects","volume":"11","author":"Shah","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.cyto.2023.156234_b0010","first-page":"2323","article-title":"Extraction Techniques and Analytical Methods for Isolation and Characterization of Lignans","volume":"11","author":"Patyra","year":"2022","journal-title":"Plants (Basel)."},{"key":"10.1016\/j.cyto.2023.156234_b0015","doi-asserted-by":"crossref","first-page":"19231","DOI":"10.1021\/jacs.9b10717","article-title":"Total biosynthesis for milligram-scale production of etoposide intermediates in a plant chassis","volume":"141","author":"Schultz","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.cyto.2023.156234_b0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12934-021-01673-5","article-title":"Synthesis of (-)-deoxypodophyllotoxin and (-)-epipodophyllotoxin via a multi-enzyme cascade in E. coli","volume":"20","author":"Decembrino","year":"2021","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.cyto.2023.156234_b0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1078155219875799","article-title":"Clinical impact of the etoposide injection shortage","volume":"26","author":"Li","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.cyto.2023.156234_b0030","first-page":"95","article-title":"Molecular mechanisms of etoposide","volume":"14","author":"Montecucco","year":"2015","journal-title":"EXCLI J."},{"key":"10.1016\/j.cyto.2023.156234_b0035","article-title":"First-line chemo-immunotherapy for extensive-stage small-cell lung cancer: A United States-based cost-effectiveness analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cyto.2023.156234_b0040","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1038\/s41598-021-93516-x","article-title":"BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy","volume":"11","author":"Hahn","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2023.156234_b0045","article-title":"Insight into the molecular mechanism of podophyllotoxin derivatives as anticancer drugs","volume":"T9","author":"Fan","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.cyto.2023.156234_b0050","article-title":"First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cyto.2023.156234_b0055","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12185-019-02791-y","article-title":"Autologous peripheral blood stem cell transplantation for relapsed\/refractory HIV-associated lymphoma: a phase II clinical study","volume":"111","author":"Hagiwara","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.cyto.2023.156234_b0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1078155219836478","article-title":"Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity","volume":"26","author":"Brooks","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.cyto.2023.156234_b0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1208\/s12249-022-02329-2","article-title":"Formulation and physicochemical and biological characterization of etoposide-loaded submicron emulsions with biosurfactant of sophorolipids","volume":"23","author":"Ma","year":"2022","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.cyto.2023.156234_b0070","doi-asserted-by":"crossref","first-page":"18059","DOI":"10.1038\/s41598-020-74809-z","article-title":"Preparation of parenteral nanocrystal suspensions of etoposide from the excipient free dry state of the drug to enhance in vivo antitumoral properties","volume":"10","author":"Martin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2023.156234_b0075","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/10717544.2020.1837293","article-title":"Enhanced oral bioavailability of an etoposide multiple nanoemulsion incorporating a deoxycholic acid derivative-lipid complex","volume":"27","author":"Jha","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.cyto.2023.156234_b0080","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1089\/adt.2021.089","article-title":"Self-assembled nanomicelles to enhance solubility and anticancer activity of etoposide","volume":"19","author":"Alsalhi","year":"2021","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.cyto.2023.156234_b0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12885-017-3980-3","article-title":"Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan","volume":"18","author":"Sarwar","year":"2018","journal-title":"BMC Cancer."},{"key":"10.1016\/j.cyto.2023.156234_b0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41580-022-00452-3","article-title":"Human topoisomerases and their roles in genome stability and organization","volume":"23","author":"Pommier","year":"2022","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.cyto.2023.156234_b0095","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/mol.119.117259","article-title":"Intercalating TOP2 poisons attenuate topoisomerase action at higher concentrations","volume":"96","author":"Atwal","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cyto.2023.156234_b0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2006.11.005","article-title":"Cellular response to etoposide treatment","volume":"252","author":"Montecucco","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cyto.2023.156234_b0105","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1073\/pnas.1204406109","article-title":"Model for MLL translocations in therapy-related leukemia involving topoisomerase II\u03b2-mediated DNA strand breaks and gene proximity","volume":"109","author":"Cowell","year":"2012","journal-title":"Proc. Natl. Acad Sci. USA"},{"key":"10.1016\/j.cyto.2023.156234_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101169","article-title":"Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play","volume":"14","author":"Zhang","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.cyto.2023.156234_b0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1124\/mol.119.116319","article-title":"T-cell protein tyrosine phosphatase is irreversibly inhibited by etoposide-quinone, a reactive metabolite of the chemotherapy drug etoposide","volume":"96","author":"Nian","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cyto.2023.156234_b0120","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/ped.14172","article-title":"Double recurrence of double cancers: Rhabdomyosarcoma and secondary AML","volume":"62","author":"Kajita","year":"2020","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.cyto.2023.156234_b0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-med-042921-112837","article-title":"Cytokine storm syndrome","volume":"74","author":"Cron","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cyto.2023.156234_b0130","doi-asserted-by":"crossref","first-page":"e250809","DOI":"10.1136\/bcr-2022-250809","article-title":"Haemophagocytic lymphocytic histiocytosis\/macrophage activation syndrome with acute inflammatory gastroenteritis","volume":"15","author":"Kolachana","year":"2022","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.cyto.2023.156234_b0135","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000525576","article-title":"Dramatic recovery after etoposide phosphate infusion for hemophagocytic lymphohistiocytosis\/macrophage activation syndrome following treatment with tisagenlecleucel in a young patient with relapsed acute lymphoblastic leukemia: A case report","volume":"145","author":"Peterlin","year":"2022","journal-title":"Acta. Haematol."},{"key":"10.1016\/j.cyto.2023.156234_b0140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-019-1033-5","article-title":"Requirement for etoposide in the treatment of pregnancy related hemophagocytic lymphohistiocytosis: A multicenter retrospective study","volume":"14","author":"Song","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.cyto.2023.156234_b0145","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/16078454.2020.1838708","article-title":"Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review","volume":"24","author":"Wang","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.cyto.2023.156234_b0150","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s41409-022-01668-9","article-title":"Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: A systematic review of literature","volume":"57","author":"Masood","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.cyto.2023.156234_b0155","doi-asserted-by":"crossref","first-page":"507","DOI":"10.5858\/arpa.2020-0802-RA","article-title":"Hemophagocytic Lymphohistiocytosis","volume":"146","author":"Ponnatt","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.cyto.2023.156234_b0160","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12519-019-00299-3","article-title":"Dilemmas in diagnosis and management of hemophagocytic lymphohistiocytosis in children","volume":"16","author":"Xu","year":"2020","journal-title":"World J. Pediatr."},{"key":"10.1016\/j.cyto.2023.156234_b0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.amjms.2018.07.004","article-title":"Hemophagocytic Lymphohistiocytosis in the Elderly","volume":"357","author":"Altook","year":"2019","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.cyto.2023.156234_b0170","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3899\/jrheum.200941","article-title":"Efficacy of moderately dosed etoposide in macrophage activation syndrome-hemophagocytic lymphohistiocytosis","volume":"48","author":"Horne","year":"2021","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cyto.2023.156234_b0175","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1111\/apa.15889","article-title":"Clinical features, diagnosis and therapy of familial haemophagocytic lymphohistiocytosis","volume":"110","author":"Janka","year":"2021","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.cyto.2023.156234_b0180","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","article-title":"Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: Consensus statements by the HLH steering committee of the histiocyte society","volume":"6","author":"Ehl","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.cyto.2023.156234_b0185","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1182\/blood-2017-10-808543","article-title":"Etoposide for HLH: The limits of efficacy","volume":"130","author":"Ehl","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.cyto.2023.156234_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953730","article-title":"Activation mechanisms of monocytes\/macrophages in adult-onset Still disease","volume":"13","author":"Tsuboi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2023.156234_b0195","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s10067-022-06184-1","article-title":"Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome","volume":"41","author":"Wang","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2023.156234_b0200","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/24725625.2020.1741073","article-title":"Successful use of short-term add-on tocilizumab for refractory adult-onset still's disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide","volume":"4","author":"Ohmura","year":"2020","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"10.1016\/j.cyto.2023.156234_b0205","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s42399-021-00998-x","article-title":"SARS-CoV-2-Induced Multisystem Inflammatory Syndrome in a Young Adult: Case Report","volume":"3","author":"Bulut","year":"2021","journal-title":"SN Compr. Clin. Med."},{"key":"10.1016\/j.cyto.2023.156234_b0210","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1186\/s12879-021-06532-7","article-title":"Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report","volume":"21","author":"Meazza Prina","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.cyto.2023.156234_b0215","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.chest.2020.10.090","article-title":"Etoposide for cytokine storm because of coronavirus disease 2019","volume":"159","author":"Delgado-L\u00f3pez","year":"2021","journal-title":"Chest."},{"key":"10.1016\/j.cyto.2023.156234_b0220","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.chest.2020.09.077","article-title":"Temple university COVID-19 research group. Etoposide as salvage therapy for cytokine storm due to coronavirus disease 2019","volume":"159","author":"Patel","year":"2021","journal-title":"Chest."},{"key":"10.1016\/j.cyto.2023.156234_b0225","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3389\/fimmu.2020.01445","article-title":"Potential treatments for COVID-19 related cytokine storm - beyond corticosteroids","volume":"11","author":"Miao","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2023.156234_b0230","doi-asserted-by":"crossref","unstructured":"Aoyagi T, Sato Y, Baba H, Shiga T, Seike I, Niitsuma Sugaya I, Takei K, Iwasaki Y, Oshima K, Kanamori H, Yoshida M, Saito K, Tokuda K, Kaku M. Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids, Front. Med. (Lausanne). 8 (2021) 718641.","DOI":"10.3389\/fmed.2021.718641"},{"key":"10.1016\/j.cyto.2023.156234_b0235","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12185-020-02888-9","article-title":"Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19","volume":"112","author":"Takami","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.cyto.2023.156234_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109826","article-title":"Etoposide-based therapy for severe forms of COVID-19","volume":"142","author":"Hamizi","year":"2020","journal-title":"Med. Hypotheses."},{"key":"10.1016\/j.cyto.2023.156234_b0245","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s15010-022-01786-y","article-title":"Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination","volume":"50","author":"Hieber","year":"2022","journal-title":"Infection."},{"key":"10.1016\/j.cyto.2023.156234_b0250","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s10875-021-01073-9","article-title":"T Cell-epstein-barr virus-associated hemophagocytic lymphohistiocytosis (HLH) occurs in Non-Asians and is associated with a T cell activation state that is comparable to primary HLH","volume":"41","author":"Shamriz","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.cyto.2023.156234_b0255","doi-asserted-by":"crossref","first-page":"e01616","DOI":"10.1016\/j.idcr.2022.e01616","article-title":"A mild, self-resolving case of Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis","volume":"30","author":"Adhikari","year":"2022","journal-title":"IDCases"},{"key":"10.1016\/j.cyto.2023.156234_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876415","article-title":"The outcome of induction therapy for EBV-related hemophagocytic lymphohistiocytosis: A model for risk stratification","volume":"13","author":"Cui","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2023.156234_b0265","doi-asserted-by":"crossref","first-page":"e935915","DOI":"10.12659\/AJCR.935915","article-title":"A case of hemophagocytic lymphohistiocytosis (HLH) secondary to T cell lymphoma and cytomegalovirus (CMV) infection and complicated by tumor lysis syndrome (TLS)","volume":"23","author":"Kilani","year":"2022","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.cyto.2023.156234_b0270","first-page":"e26504","article-title":"A case report of hemophagocytic lymphohistiocytosis (HLH) - An unusual complication of dengue infection","volume":"14","author":"Acharya","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.cyto.2023.156234_b0275","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.4081\/hr.2019.8268","article-title":"Influenza virus B-associated hemophagocytic lymphohistiocytosis","volume":"11","author":"Gao","year":"2019","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.cyto.2023.156234_b0280","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5582\/ddt.2020.03069","article-title":"Haemophagocytic lymphohistiocytosis in human immunodeficiency virus: A systematic review of literature","volume":"14","author":"Fazal","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.cyto.2023.156234_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.681055","article-title":"Case report: Rapid recognition and immune modulation of secondary HLH due to disseminated HSV infection","volume":"9","author":"McKeone","year":"2021","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.cyto.2023.156234_b0290","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1111\/apa.15973","article-title":"Virus-triggered secondary hemophagocytic lymphohistiocytosis","volume":"110","author":"Imashuku","year":"2021","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.cyto.2023.156234_b0295","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00277-022-04946-0","article-title":"L-DEP regimen is effective as an initial therapy for adult EBV-HLH","volume":"101","author":"Chen","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cyto.2023.156234_b0300","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13023-021-01909-y","article-title":"Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein-Barr virus infection","volume":"16","author":"Ma","year":"2021","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.cyto.2023.156234_b0305","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000514920","article-title":"The efficacy of etoposide-based therapy in adult secondary hemophagocytic lymphohistiocytosis","volume":"144","author":"Naymagon","year":"2021","journal-title":"Acta Haematol."},{"key":"10.1016\/j.cyto.2023.156234_b0310","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s12185-022-03430-9","article-title":"Anakinra for the treatment of adult secondary HLH: A retrospective experience","volume":"116","author":"Naymagon","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.cyto.2023.156234_b0315","article-title":"A review of current and emerging therapeutic options for hemophagocytic lymphohistiocytosis","author":"Summerlin","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.cyto.2023.156234_b0320","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/15384047.2021.1996139","article-title":"Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis","volume":"22","author":"Song","year":"2021","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cyto.2023.156234_b0325","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12887-016-0649-z","article-title":"Acute myeloid leukemia following etoposide therapy for EBV-associated hemophagocytic lymphohistiocytosis: a case report and a brief review of the literature","volume":"16","author":"Pan","year":"2016","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.cyto.2023.156234_b0330","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/ACI.0000000000000865","article-title":"Recent advances in the treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome","volume":"22","author":"Jesudas","year":"2022","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2023.156234_b0335","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s00277-022-04960-2","article-title":"Practice patterns and outcomes of hemophagocytic lymphohistiocytosis in adults: A 2-decade provincial retrospective review","volume":"101","author":"Croden","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cyto.2023.156234_b0340","doi-asserted-by":"crossref","first-page":"142","DOI":"10.14740\/jh1033","article-title":"Immune Checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in a patient with squamous cell carcinoma","volume":"11","author":"Marar","year":"2022","journal-title":"J. Hematol."},{"key":"10.1016\/j.cyto.2023.156234_b0345","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MPH.0000000000001552","article-title":"Hemophagocytic lymphohistiocytosis: A rare complication of an ultrarare lysosomal storage disease","volume":"42","author":"Chabchoub","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.cyto.2023.156234_b0350","article-title":"Recurrent inflammatory flares in HIV-infected patients: Consider castleman disease!","volume":"5","author":"Jegerlehner","year":"2017","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"10.1016\/j.cyto.2023.156234_b0355","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.arcped.2010.08.018","article-title":"Treatment of severe hemophagocytic syndrome associated with visceral leishmaniasis","volume":"17","author":"Bouguila","year":"2010","journal-title":"Arch. Pediatr."},{"key":"10.1016\/j.cyto.2023.156234_b0360","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12879-020-05016-4","article-title":"Successful treatment of mycobacterial infection associated hemophagocytic lymphohistiocytosis with etoposide and anti-tuberculous therapy: A case report","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.cyto.2023.156234_b0365","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215366","article-title":"Haemophagocytic lymphohistiocytosis (HLH): a rare but potentially fatal association with Plasmodium vivax malaria","volume":"2016","author":"Ullah","year":"2016","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.cyto.2023.156234_b0370","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s000110300065","article-title":"Impact of topoisomerase II inhibition on cytokine and chemokine production","volume":"52","author":"Verdrengh","year":"2003","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.cyto.2023.156234_b0375","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4161\/cbt.29922","article-title":"Production of IL-1\u03b2 by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine","volume":"15","author":"Wong","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cyto.2023.156234_b0380","article-title":"Macrophage activation syndrome in adults: Characteristics, outcomes, and therapeutic effectiveness of etoposide-based regimen","volume":"13","author":"He","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2023.156234_b0385","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s10020-021-00308-0","article-title":"Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome","volume":"27","author":"Palmblad","year":"2021","journal-title":"Mol. Med."},{"key":"10.1016\/j.cyto.2023.156234_b0390","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-022-01365-6","article-title":"The emerging role of pyroptosis in pediatric cancers: From mechanism to therapy","volume":"15","author":"Wang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cyto.2023.156234_b0395","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/apa.15900","article-title":"Hyperinflammation: On the pathogenesis and treatment of macrophage activation syndrome","volume":"110","author":"Andersson","year":"2021","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.cyto.2023.156234_b0400","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ijc.21367","article-title":"Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection","volume":"118","author":"Asakawa","year":"2006","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.cyto.2023.156234_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.922212","article-title":"Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy","volume":"13","author":"Gong","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2023.156234_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109130","article-title":"Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach","volume":"111","author":"Aliyu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2023.156234_b0415","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1272\/jnms.JNMS.2020_87-307","article-title":"Changes in cytokine profile during initial treatment of pediatric hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus","volume":"87","author":"Ueda","year":"2020","journal-title":"J. Nippon Med. Sch."},{"key":"10.1016\/j.cyto.2023.156234_b0420","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/art.41763","article-title":"Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkers","volume":"73","author":"Kessel","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2023.156234_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cyto.2023.156234_b0430","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s12885-020-07102-x","article-title":"Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization","volume":"20","author":"Kang","year":"2020","journal-title":"BMC Cancer."},{"key":"10.1016\/j.cyto.2023.156234_b0435","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lfs.2019.02.003","article-title":"Leukemia-derived exosomes induced IL-8 production in bone marrow stromal cells to protect the leukemia cells against chemotherapy","volume":"221","author":"Chen","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.cyto.2023.156234_b0440","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3390\/biom10101450","article-title":"Nonhistone proteins HMGB1 and HMGB2 differentially modulate the response of human embryonic stem cells and the progenitor cells to the anticancer drug etoposide","volume":"10","author":"Bagherpoor","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.cyto.2023.156234_b0445","doi-asserted-by":"crossref","first-page":"C1318","DOI":"10.1152\/ajpcell.00616.2005","article-title":"The extracellular release of HMGB1 during apoptotic cell death","volume":"291","author":"Bell","year":"2006","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"10.1016\/j.cyto.2023.156234_b0450","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1172\/JCI127471","article-title":"cGAS\/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity","volume":"129","author":"Wang","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2023.156234_b0455","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/nar\/gkp067","article-title":"HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha","volume":"37","author":"Stros","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cyto.2023.156234_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108264","article-title":"Topoisomerase 2 inhibitor etoposide promotes interleukin-10 production in LPS-induced macrophages via upregulating transcription factor Maf and activating PI3K\/Akt pathway","volume":"101","author":"Zhang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2023.156234_b0465","doi-asserted-by":"crossref","first-page":"13627","DOI":"10.3390\/ijms222413627","article-title":"Chemotherapeutic drug-regulated cytokines might influence therapeutic efficacy in HCC","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2023.156234_b0470","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jca.21734","article-title":"Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma","volume":"34","author":"Park","year":"2019","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.cyto.2023.156234_b0475","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7754\/Clin.Lab.2019.190214","article-title":"Comparison of various hematopoietic stem cell mobilization regimens in patients with lymphoma and myeloma","volume":"65","author":"Yilmaz","year":"2019","journal-title":"Clin. Lab."},{"key":"10.1016\/j.cyto.2023.156234_b0480","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1182\/blood.2021013549","article-title":"Expansion of CD4dimCD8+ T cells characterizes macrophage activation syndrome and other secondary HLH","volume":"140","author":"De Matteis","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2023.156234_b0485","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/eji.202149528","article-title":"Immunopathology caused by impaired CD8+ T-cell responses","volume":"52","author":"Aichele","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cyto.2023.156234_b0490","doi-asserted-by":"crossref","first-page":"e13487","DOI":"10.1111\/dth.13487","article-title":"Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment","volume":"33","author":"Ohuchi","year":"2020","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.cyto.2023.156234_b0495","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3389\/fimmu.2019.01526","article-title":"Daurinol attenuates autoimmune arthritis via stabilization of Nrp1-PTEN-Foxp3 signaling in regulatory T cells","volume":"10","author":"Park","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2023.156234_b0500","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1465-9921-15-82","article-title":"Moxifloxacin modulates inflammation during murine pneumonia","volume":"15","author":"Beisswenger","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.cyto.2023.156234_b0505","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/08820139.2020.1797778","article-title":"A review of immunomodulatory effects of fluoroquinolones","volume":"50","author":"Assar","year":"2021","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.cyto.2023.156234_b0510","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.709075","article-title":"Insight into the molecular mechanism of podophyllotoxin derivatives as anticancer drugs","volume":"9","author":"Fan","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.cyto.2023.156234_b0515","first-page":"531","article-title":"Cytokine nanosponges suppressing overactive macrophages and dampening systematic cytokine storm for the treatment of hemophagocytic lymphohistiocytosis","volume":"21","author":"Wang","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.cyto.2023.156234_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114659","article-title":"SILAC-based chemoproteomics reveals a neoligan analogue as an anti-inflammatory agent targeting IRGM to ameliorate cytokine storm","volume":"241","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cyto.2023.156234_b0525","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.3390\/ijms222313009","article-title":"Pathogenesis and treatment of cytokine storm induced by infectious diseases","volume":"22","author":"Tang","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:48:45Z","timestamp":1760910525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466623001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":105,"alternative-id":["S1043466623001126"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156234","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etoposide: A rider on the cytokine storm","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156234"}}